Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

Diabetology & Metabolic Syndrome

Carlos Antonio Negrato¹  Marilia Brito Gomes² 

[1] Department of Internal Medicine, Bauru’s Diabetics Association, 17012-433, Bauru, São Paulo, Brazil;Department of Internal Medicine, Diabetes Unit, State University Hospital of Rio de Janeiro, Avenida 28 de Setembro, 77, 3° andar CEP 20.551-030, Rio de Janeiro, Brazil

关键词: Chronic diseases;    Diabetes mellitus;    Biochemical action;    Alpha-lipoic acid;   

Others  :  1138308
DOI  :  10.1186/1758-5996-6-80

 received in 2014-05-05, accepted in 2014-07-11,  发布年份 2014

【 摘 要 】

Alpha-lipoic acid is a naturally occurring substance, essential for the function of different enzymes that take part in mitochondria’s oxidative metabolism. It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid have many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways. These above-mentioned actions have been shown in experimental studies emphasizing the use of alpha-lipoic acid as a potential therapeutic agent for many chronic diseases with great epidemiological as well economic and social impact such as brain diseases and cognitive dysfunctions like Alzheimer disease, obesity, nonalcoholic fatty liver disease, burning mouth syndrome, cardiovascular disease, hypertension, some types of cancer, glaucoma and osteoporosis. Many conflicting data have been found concerning the clinical use of alpha-lipoic acid in the treatment of diabetes and of diabetes-related chronic complications such as retinopathy, nephropathy, neuropathy, wound healing and diabetic cardiovascular autonomic neuropathy. The most frequent clinical condition in which alpha-lipoic acid has been studied was in the management of diabetic peripheral neuropathy in patients with type 1 as well type 2 diabetes. Considering that oxidative stress, a imbalance between pro and antioxidants with excessive production of reactive oxygen species, is a factor in the development of many diseases and that alpha-lipoic acid, a natural thiol antioxidant, has been shown to have beneficial effects on oxidative stress parameters in various tissues we wrote this article in order to make an up-to-date review of current thinking regarding alpha-lipoic acid and its use as an antioxidant drug therapy for a myriad of diseases that could have potential benefits from its use.

【 授权许可】

   
2014 Gomes and Negrato; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Golbidi S, Badran M, Laher I: Diabetes and alpha lipoic Acid. Front Pharmacol 2011, 2:69.
• [2]Reed LJ: From lipoic acid to multi-enzyme complexes. Protein Sci 1998, 7(1):220-224.
• [3]Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM: Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009, 1790(10):1149-1160.
• [4]Snell EE, Strong FM, Peterson WH: Growth factor for bacteria.VI Fractionation and properties of an accessory factor for lactic acid bacteria. Bichem J 1937, 31:1789-1799.
• [5]Reed LJ, De Busk BG, Gunsalus IC, Hornberger CS: Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science 1951, 114:93-94.
• [6]Bock E, Schneeweiss J: Ein Beitrag zur Therapie der neuropathia diabetic. Munchner Med Wochenschrift 1959, 43:1911-1912.
• [7]Wray DW, Nishyyama SK, Harris RA, Zhao J, McDaniel J, Fjeldstad AS, Witman MA, Ives SJ, Barrett-O’Keefe Z, Richardson RS: Acute reversal of endothelial dysfunction in the elderly following antioxidant consumption. Hypertension 2012, 59:818-824.
• [8]McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J: Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis 2011, 10:217.
• [9]Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B: Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation 2008, 117(3):421-428.
• [10]Ying Z, Kherada N, Farrar B, Kampfrath T, Chung Y, Simonetti O, Deiuliis J, Desikan R, Khan B, Villamena F, Sun Q, Parthasarathy S, Rajagopalan S: Lipoic acid effects on established atherosclerosis. Life Sci 2010, 86(3–4):95-102.
• [11]Ziegler D, Reljanovic M, Mehnert H, Gries FA: α Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999, 107:421-430.
• [12]Packer L, Kraemer K, Rimbach G: Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001, 17:888-895.
• [13]Vasdev S, Ford CA, Parai S, Longerich L, Gadag V: Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 2000, 18(5):567-573.
• [14]Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G: Lipoic acidi and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 2007, 12:195-206.
• [15]Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL: Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 2011, 155A:1939-1948.
• [16]Al Abdan M: Alfa-lipoic acid controls tumor growth and modulates hepatic redox state in Ehrlich-ascites-carcinoma-bearing mice. Scientific World Journal 2012, 2012:509838.
• [17]Szelag M, Mikulski D, Molski M: Quantum-chemical investigation of the structure and the antioxidant properties of α-lipoic acid and its metabolites. J Mol Model 2012, 18:2907-2916.
• [18]Padmalayam I, Hasham S, Saxena U, Pillarisetti S: Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes 2009, 58:600-608.
• [19]McLain AL, Cormier PJ, Kinter M, Szweda LI: Glutathionylation of α-ketoglutarate dehydrogenase: the chemical nature and relative susceptibility of the cofactor lipoic acid to modification. Free Radic Biol Med 2013, 61C:161-169.
• [20]Hassan BH, Cronan JE: Protein-protein interactions in assembly of lipoic acid on the 2-oxoacid dehydrogenases of aerobic metabolism. J Biol Chem 2011, 286:8263-8276.
• [21]Moini H, Tirosh O, Park YC, Cho KJ, Packer L: R-alpha-lipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys 2002, 397(2):384-391.
• [22]A-Vadlapudi AD, Vadlapatla RK, Mitra AK: Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. Curr Drug Targets 2012, 13:994-1003.
• [23]Scott BC, Aruoma OI, Evans PJ, O’Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B: Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 1994, 20(2):119-133.
• [24]Packer L, Witt EH, Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med 1995, 19(2):227-250.
• [25]Trujillo M, Radi R: Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols. Arch of Biochem and Biophys 2002, 397(1):91-98.
• [26]Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A: A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds. Pharm World Sci 1997, 19(6):283-286.
• [27]Suzuki YJ, Tsuchiya M, Packer L: Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1991, 15(5):255-263.
• [28]Suzuki YJ, Tsuchiya M, Packer L: Antioxidant activities of dihydrolipoic acid and its structural homologues. Free Radic Res Commun 1993, 18(2):115-122.
• [29]Devasagayam TP, Di Mascio P, Kaiser S, Sies H: Singlet oxygen induced single-strand breaks in plasmid pBR322 DNA: the enhancing effect of thiols. Biochim Biophys Acta 1991, 1088(3):409-412.
• [30]Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, Packer L: Dihydrolipoic acid–a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol 1992, 44(8):1637-1649.
• [31]Haenen GR, Bast A: Scavenging of hypochlorous acid by lipoic acid. Biochem Pharmacol 1991, 42(11):2244-2246.
• [32]Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R: Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. J Endocrinol 2012, 214(1):11-20.
• [33]Koriyama Y, Nakayama Y, Matsugo S, Kato S: Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res 2013, 1499:145-157.
• [34]Wilking M, Ndiaye M, Mukhtar H, Ahmad N: Circadian rythms connections to oxidative stress: implications for human health. Antioxid Redox Signal 2013, 19:192-208.
• [35]Dicter N, Madar Z, Tirosh O: Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr 2002, 132(10):3001-3006.
• [36]Rouchette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C: Direct and indirect antioxidant properties of α -lipoic acid. Mol Nutr Food Res 2013, 57:114-125.
• [37]Moini H, Packer L, Saris N-E: Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 2002, 182:84-90.
• [38]Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M: keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24:10941-10953.
• [39]Dinkova-kostova AT, Talalay P: Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 2008, 52:S128-S138.
• [40]Frizzell N, Baynes JW: Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem 2013, 5(10):1075-1078.
• [41]Ou P, Tritscheler HJ, Wolff SP: Thioctic (lipoic acid): a therapeutical metal-chelating antioxidant? Biochem Pharmacol 1995, 50:123-126.
• [42]Bast A, Haenen GR: Lipoic acid: a multifunctional antioxidant. Biofactors 2003, 17(1–4):207-213.
• [43]Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM: Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004, 11(9):1135-1146.
• [44]Yaworsky K, Somwar R, Ramlal T, Tritschler HJ, Klip A: Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Diabetologia 2000, 43(3):294-303.
• [45]Estrada DE, Ewart HS, Tsakiridis T, Volchuk A, Ramlal T, Tritschler H, Klip A: Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes 1996, 45(12):1798-1804.
• [46]Henriksen EJ, Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ: Stimulation by alpha-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats. Life Sci 1997, 61(8):805-812.
• [47]Yamamoto Y, Gaynor RB: Therapeutical potential of inhibition of the NFkb pathway in the treatment of inflammation and cancer. J Clin Invest 2001, 107(2):135-142.
• [48]El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205(10):2409-2417.
• [49]Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997, 46(9):1481-1490.
• [50]Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S: Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function. Inflamm Res 2011, 60(3):219-225.
• [51]Zembron-Lacny A, Gajeswski M, Naczac M, Dziewiecka H, Siatkkowski I: Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status. J Physiolo 2013, 69:397-404.
• [52]Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005, 111(3):343-348.
• [53]Steinberg GR, Kemp BE: AMPK in health and disease. Physiol Rev 2009, 89(3):1025-1078.
• [54]Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108(8):1167-1174.
• [55]Shen QW, Zhu MJ, Tong J, Ren J, Du M: Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol 2007, 293(4):C1395-C1403.
• [56]Wang Y, Li X, Guo Y, Chan L, Guan X: Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism 2010, 59(7):967-976.
• [57]Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, Chan CB, Wheeler MB: Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 2006, 49(7):1587-1598.
• [58]Koh G, Yang EJ, Kim MK, Lee SA, Lee DH: Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic β-cells. Biol Pharm Bull 2013. [Epub ahead of print]. doi:10.12478/bpb.13-00292
• [59]Ramamurthy S, Ronnet G: AMP-activated protein kinase (AMPK) and energy sensing in the brain. Exp Neurobiol 2012, 21(2):52-60.
• [60]Blazquez C, Geelen MJ, Velasco G, Guzmán M: The AMP activated protein kinase prevents ceramide synthesis de novo and astrocytes. FEBS Lett 2001, 489(2–3):149-153.
• [61]Nakatsu Y, Kotake Y, Hino A, Ohta S: Activation of AMO-activated protein kinase by tributyltin induces neuronal cell death. Toxicol Appl Pharmacol 2008, 230(3):358-363.
• [62]Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU: Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004, 10(7):727-733.
• [63]Seo EY, Ha AW, Kim WK: α lipoic acid reduced weight gain and improved lipid profile in rats fed with high fat diet. Nutr Res Pract 2012, 6:195-200.
• [64]Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare ML, Nwankwo IE, Marini C, Tayebati SK: Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. Int J Mol Sci 2013, 14(3):4580-4595.
• [65]Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS: Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways. J Biol Chem 2003, 278(37):34823-34833.
• [66]Wang Y, Dong W, Ding X, Wang F, Wang Y, Chen X, Yu L, Li X, Zhang A, Peng Y: Protective effect of α-lipoic acid on islet cells co-cultured with 3T3L1 adipocytes. Exp Ther Med 2012, 4(3):469-474.
• [67]Tian YF, He CT, Chen YT, Hsieh PS: Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World J Gastroenterol 2013, 19(18):2761-2771.
• [68]Ong SL, Vohra H, Zhang Y, Sutton M, Whitworth JA: The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. Oxid Med Cell Longev 2013, 2013:517045. doi:10.1155/2013/517045. Epub 2013 Feb 26
• [69]Li CJ, Lv L, Li H, Yu D: Cardiac fibrosis and dysfunctionin experimental diabetic cardiomyopathy are amelioreted by alpha-lipoic acid. Cardiovasc Diabetol 2012, 11:142. doi:10.1186/1475-2840-11-142
• [70]Deng C, Sun Z, Tong G, Yi W, Ma L, Zhao B, Cheng L, Zhang J, Cao F, Yi D: α-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS One 2013, 8(3):e58371.
• [71]Yi X, Nickeleit V, James LR, Maeda N: α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. J Diabetes Complications 2011, 25(3):193-201.
• [72]Inman DM, Lambert WS, Calkins DJ, Horner PJ: α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS One 2013, 8(6):e65389.
• [73]Jha MK, Jeon S, Suk K: Pyruvate Dehydrogenase Kinases in the nervous system: their principal functions in Neuronal-glial metabolic interaction and Neuro-metabolic disorders. Curr Neuropharmacol 2012, 10:393-403.
• [74]Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, Oliveira CR, Moreira PI: Metabolic alterations induced by sucrose intake and Alzheimer’s disease promote similar brain mitochondrial abnormalities. Diabetes 2012, 61(5):1234-1242.
• [75]Maher PA, Schubert DR: Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother 2009, 9:617-630.
• [76]Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B: Progress in the development of new drugs in Alzheimer’s disease. J Nutr Health Aging 2011, 15(1):45-57.
• [77]Sancheti H, Akopian G, Yin F, Brinton RD, Walsh JP, Cadenas E: Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer’s disease. PLoS One 2013, 8:e69830.
• [78]Gupta A, Bisht B, Dey CS: Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology 2011, 60(6):910-920.
• [79]Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G: Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev 2008, 60:1463-1470.
• [80]Hager K, Kenklies M, McAfoose J, Engel J, Münch G: Alpha-lipoic acid as a new treatment option for Alzheimer’s disease–a 48 months follow-up analysis. J Neural Transm Suppl 2007, 72:189-193.
• [81]Cho JY, Um HS, Kang EB, Cho IH, Kim CH, Cho JS, Hwang DY: The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer’s disease in NSE/APPsw-transgenic mice. Int J Mol Med 2010, 25(3):337-346.
• [82]Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Alfredo Martínez J, Moreno-Aliaga MJ: Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats. Eur J Nutr 2013, 52(2):779-787.
• [83]Deiuliis JA, Kampfrath T, Ying Z, Maiseyeu A, Rajagopalan S: Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant mice. Lipids 2011, 46:1021-1032.
• [84]Lamb RE, Goldstein BJ: Modulating an oxidative-inflmmatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract 2008, 62(7):1087-1095.
• [85]Xiao C, Giacca A, Lewis GF: Short-term oral α-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men. Am J Physiol Endocrinol Metab 2011, 301:E736-E741.
• [86]Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y: Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring) 2011, 19(8):1647-1653.
• [87]Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, Kim DW, Kim MS, Park JY, Park KG, Lee HJ, Lee IK, Lim S, Jang HC, Lee KH, Lee KU: Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med 2011, 124:85.e1-85.e8.
• [88]Ratliff JC, Palmese LB, Reutenauer EL, Tek C: An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses 2013, 7:1-13. Jose516 @ hotmail.com
• [89]Lean MEJ: Sibutramine: a review of clinical efficacy. In J Obes 1997, 21:30S-36S.
• [90]Lazo M, Clark JM: The epidemiology of nonalcoolic faty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
• [91]Dixon JB, Bhathal PS, O’Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
• [92]Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA: Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem 2012, 23(12):1676-1684.
• [93]Jung TS, Kim SK, Shin HJ, Jeon BT, Hahm JR, Roh GS: α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats. Liver Int 2012, 32:1565-1573.
• [94]Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA: Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity 2012, 20(10):1974-1983.
• [95]Chen WL, Kang CH, Wang SG, Lee HM: α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia 2012, 55(6):1824-1835.
• [96]Chong ZZ, Shang YC, Wang S, Maiesse K: SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets 2012, 16:167-178.
• [97]Gurvits GE, Tan A: Burning mouth syndrome. World J Gastroenterol 2013, 7:665-672.
• [98]Cavalcanti DR, da Silveira FR: Alpha lipoic acid in burning mouth syndrome–a randomized double-blind placebo-controlled trial. J Oral Pathol Med 2009, 38:254-261.
• [99]Femiano F, Lanza A, Buonaiuto C, Gombos F, Nunziata M, Cuccurullo L, Cirillo N: Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105:e22-e27.
• [100]Femiano F: Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol 2002, 51:405-409.
• [101]Hu G, Jousilhati P, Qiao Q, Katoh S: Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 2005, 48:856-861.
• [102]Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
• [103]Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL, Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110(5):637-641.
• [104]McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF Jr, Vita JA: Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007, 9(4):249-255.
• [105]Durand M, Mach N: Alpha lipoic acid and its antioxidant against cancer and diseases of central sensitization. Nutr Hosp 2013, 28:1031-1038.
• [106]Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K: α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett 2013, 335(2):472-478.
• [107]Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R: Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther 2012, 13(14):1425-1435.
• [108]Kim JI, Cho SR, Lee CM, Park ES, Kim KN, Kim HC, Lee HY: Induction of ER stress-mediated apoptosis by α-Lipoic Acid in A549 cell lines. Korean J Thorac Cardiovasc Surg 2012, 45(1):1-10.
• [109]Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L: The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 2003, 37(2):213-223.
• [110]Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M: Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs 2012, 30:200-211.
• [111]Diesel B, Kulhanek-Heinze S, Höltje M, Brandt B, Höltje HD, Vollmar AM, Kiemer AK: Alpha-lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochemistry 2007, 46(8):2146-2155.
• [112]Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, Bilen H, Sahin A, Yuksel TN: The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone. Eur J Pharmacol 2013. doi:S0014-2999 (13)00555-4. 10.1016
• [113]Xiao Y, Cui J, Shi Y, Le G: Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet. Nutr Res 2011, 31(4):309-317.
• [114]Skyler J, Oddo C: Diabetes trends in the USA. Diabetes Metab Res Ver 2002, 18:S21-S26.
• [115]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalences of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [116]The Diabetes Control and Complications Trial Study Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993, 329:977-986.
• [117]The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with diabetes type 1. N Engl J Med 2005, 353:2643-2653.
• [118]Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
• [119]Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA: Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol 2013, 50(5):743-752. Epub 2012 Jun 12
• [120]Gomes MB, Giannella-Neto D, Faria M, Tambascia MA, Fonseca RM, Rea RR, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S: Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multicenter study in Brazil. Rev Diabet Stud 2006, 3:82-87.
• [121]American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care 2008, 31:596-615.
• [122]Cobas RA, Ferraz MB, Matheus ASM, Tannus LRM, Negrato CA, Araújo LA, Dib SA, Gomes MB, Brazilian Type 1 Diabetes Study Group: The cost of type 1 diabetes: a nationwide multicentre study in Brazil. Bull World Health Organ 2013, 91:434-440.
• [123]Ceriello A, Sudhesh K, Piconi L, Esposito K, Giugliano D: Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007, 30(3):649-654.
• [124]Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care 2003, 26(5):1374-1379.
• [125]Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R: Plasma PAF–acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2009, 85:61-68.
• [126]Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100(10):1134-1146.
• [127]van Vliet M, Van der Heyden JC, Diamant M, Von Rosenstiel IA, Schindhelm RK, Aanstoot HJ, Veeze HJ: Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic Risk. J Pediatr 2010, 156(6):923-929.
• [128]Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003, 52(1):1-8.
• [129]Chang YC, Chuang LM: The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res 2010, 2(3):316-331.
• [130]Singh R, Barden A, Mori T, Beilin L: Advanced glycation end- products: a review. Diabetologia 2001, 44(2):129-146.
• [131]Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19(3):257-267.
• [132]Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. FASEB J 1992, 6(11):2905-2914.
• [133]Di Mario U, Pugliese G: 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia 2001, 44(6):674-692.
• [134]Udupa AS, Nahar PS, Shah SH, Kshirsagar MJ, Ghongane BB: Study of comparative effects of antioxidants on insulin sensitivity in type 2 diabetes mellitus. J Clin Diagn Res 2012, 6(9):1469-1473.
• [135]Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A: Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha- lipoic acid: a randomized double-blinded placebo-controlled study. Asia Pac J Clin Nutr 2012, 21(1):12-21.
• [136]de Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK: The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract 2011, 92(2):253-260.
• [137]Santos JM, Kowluru RA: Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci 2011, 52(12):8791-8798.
• [138]Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F, Nawroth P, Brownlee M, Hammes HP: Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006, 49(5):1089-1096.
• [139]Haritoglou C, Gerss J, Hammes HP, Kampik A, Ulbig MW, RETIPON Study Group: Alpha-lipoic acid for the prevention of diabetic macular edema. Ophthalmologica 2011, 226(3):127-137.
• [140]Nebbioso M, Federici M, Rusciano D, Evangelista M, Pescosolido N: Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol Ther 2012, 14(3):257-263.
• [141]Yi X, Xu L, Hiller S, Kim HS, Nickeleit V, James LR, Maeda N: Reduced expression of lipoic acid synthase accelerates diabetic nephropathy. J Am Soc Nephrol 2012, 23(1):103-111.
• [142]Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C: Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005, 67(4):1371-1380.
• [143]Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Urich H, Wahl P, Ziegler R, Tritschler H, Halliwell B, Nawroth PP: alpha- Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999, 26(11–12):1495-1500.
• [144]Cicek M, Yıldırır A, Okyay K, Yazici AC, Aydinalp A, Kanyilmaz S, Muderrisoglu H: Use of alpha-lipoic acid in prevention of contrast- induced nephropathy in diabetic patients. Ren Fail 2013, 35(5):748-753.
• [145]Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, Kim SB, Park JS: Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol 2007, 27(1):70-74.
• [146]Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP: Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001, 52(3):175-183.
• [147]Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, Pleiner J: Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest 2010, 40(2):148-154.
• [148]Chen SA, Chen HM, Yao YD, Hung CF, Tu CS, Liang YJ: Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. Eur J Pharm Sci 2012, 47(5):875-883.
• [149]Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997, 20(3):369-373.
• [150]Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL: Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 2013, 56(8):1835-1844.
• [151]Ziegler D: Diagnosis and mangement of diabetic peripheral neuropathy. Diabet Med 1996, 13(suppl 1):S34-S38.
• [152]Dyck PJ, Davies JL, Litchy WJ, O’Brien PC: Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997, 49(1):229-239.
• [153]Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995, 38(12):1425-1433.
• [154]Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999, 31(3):171-179.
• [155]Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999, 22(8):1296-1301.
• [156]Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D: Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999, 16(12):1040-1043.
• [157]Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D, SYDNEY Trial Study Group: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003, 26(3):770-776.
• [158]Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006, 29(11):2365-2370.
• [159]Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ: Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011, 34(9):2054-2060.
• [160]Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004, 21(2):114-121.
• [161]Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ: Alpha lipoic acid for symptomatic neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. Int J Endocrinol 2012, 2012:456279. doi:10.1155/2012/456279
• [162]Bertolloto F, Massome A: Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Drugs 2012, 12:29-34.
• [163]Vasudevan D, Naik MM, Mukaddam QI: Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. Results of a pilot study. Ann Indian Acad Neurol 2014, 17:19-24. doi:10.4103/0972-2327.128535
• [164]Patel N, Mishra V, Patel P, Dikshot RK: A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord 2014, 13:62.
• [165]Bresciani E, Busi A, Bazzigaluppi E, Balestere G: Insulin autoimmune syndrome induced by α lipoic acid in a Caucasian woman: case report. Diabetes Care 2011, 34:e146.
• [166]Mooradian AD, Haas MJ: Glucose-induced endoplasmic reticulum stress is independent of oxidative stress: a mechanistic explanation for the failure of antioxidant therapy in diabetes. Free Radic Biol Med 2011, 50:1140-1143.